Coronary Artery Disease
A single arm study with resolute Onyx in One-Month DAPT for High-Bleeding Risk Patients who are considered One month Clear.
Principal Investigator: Dr. Srinivasa Potluri
Locations: THHBP, Baylor McKinney
IRB Number: 018-620
Trial Status: Enrolling
Exclusions: Pregnant and Breastfeeding women; Subjects requiring planned PCI 1 month of index procedure; Procedure planned to require non study stents, stand alone POBA, or stand alone artherectomy,; Active bleeding at time of inclusion,; Cardiogenic shock,; Subject with planned surgery or procedure necessitating discontinuation of DAPT within 1 month following index procedure; hypersensitivity or contraindication to aspirin/heparin/antiplatelet medications, drugs such as zotarolimus, cobalt, nickel, platinum, chromium, stainless steel; PCI during previous 6 monthsfor a lesion other than target lesion of the index procedure; participation in another study within 12 months after index procedure, subjects with life expectancy < 2 years
Change in Care: : Participating in this study will change your care in that you will have additional lab work, EKG and a clinic follow up visit
Onyx ONE Clear: A Single Arm Study with Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients who are considered One month Clear.
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.